DDDestyn Dicharry

Destyn Dicharry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Destyn Dicharry has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antimicrobial Stewardship in Vancomycin-Resistant Enterococcus faecalis: Clinical Study Evaluating Antimicrobial Susceptibility Patterns and Antibacterial Regimens

    by Samantha A. Tolbert, Mollie V. Day, Aline Arif, Preston H. Tolbert, Destyn Dicharry, Alexandre E. Malek

    Background: Vancomycin-resistant enterococci (VRE) Enterococcus faecalis (E. faecalis) remains largely ampicillin-susceptible, yet broad-spectrum agents are frequently used empirically (i.e., daptomycin and linezolid). Despite its frequent susceptibility to ampicillin, VRE E. faecalis is often managed with broad-spectrum antimicrobials, raising concerns about overtreatment and antimicrobial stewardship. Resistance mechanisms vary, with vancomycin resistance mediated by vanA/vanB operons and beta-lactams by altered penicillin binding proteins. These distinct mechanisms help explain why VRE E. faecalis isolates may remain susceptible to ampicillin, supporting its potential use in clinical isolates. This study aims to describe the antibacterial susceptibility results of Enterococcus faecalis VRE and assess antibiotics use in clinical settings in a tertiary medical center. Methods: This was a single-center, retrospective, descriptive study of hospitalized and outpatient adults with Enterococcus faecalis VRE isolates identified between 1 June 2018 and 15 March 2025. We excluded individuals with concomitant non-Enterococcus faecalis VRE infections and those aged 32 mcg/mL per the 35th edition of the Clinical and Laboratory Standards Institution breakpoints. Results: A total of 337 patients were screened; 114 met inclusion criteria. The cohort was 54% female, 50% Black, and 48% White, with 54% having hypertension, 36% diabetes, and 19% a history of multidrug-resistant organism carriage. The most common source of infection was urinary (67%), followed by skin and soft tissue infections and bone/joint infections (11% each). All isolates were vancomycin-resistant; 82% were susceptible to ampicillin, 84% to nitrofurantoin, 61% to daptomycin, and 70% to linezolid. Antimicrobial regimens varied, with daptomycin being the most used agent (19%). No patients in the aminopenicillin group experienced 30-day mortality, whereas two patients (3%) in the non-aminopenicillin group died within 30 days. Acute kidney injury occurred in four patients (29%) in the aminopenicillin group compared with four patients (7%) in the non-aminopenicillin group, representing a significantly higher incidence in the aminopenicillin group (p = 0.037). However, myalgia, elevated creatine phosphokinase, and thrombocytopenia were more common in the non-aminopenicillin group. Conclusions: Despite higher susceptibility to ampicillin and nitrofurantoin, daptomycin was the most used agent for VRE E. faecalis infections. These findings highlight a need for improved antimicrobial stewardship and further clinical studies to guide optimal therapy.

  • Open Access

    Clinical Features of Multidrug-Resistant Gram-Negative Bacteremia: A Comparative Study of Cancer and Non-Cancer Patients

    by Destyn Dicharry, Deborah G. Smith, Muhammad H. Khan, Michelle Self, Cameron Parikh, Alexandre E. Malek

    Multidrug-resistant Gram-negative bacteremia (MDR-GNB) is a significant health threat associated with increased morbidity and mortality rates. Patients with cancer are particularly vulnerable to MDR-GNB due to immunosuppression and frequent healthcare exposure. The aim of this study was to evaluate risk factors, 30-day mortality, and outcomes in cancer and non-cancer patients. We conducted a retrospective study of adult patients aged 18 years or older with MDR-GNB who were hospitalized at Ochsner LSU Health—Academic Medical Center between January 2018 and July 2022. We collected data about demographics, comorbidities, cancer diagnosis, causative organisms, infection source, antibiotic therapy, and clinical outcomes. A total of 112 patients with MDR-GNB were included, where 31 patients (27.7%) had cancer and 81 patients (72.3%) did not. Cancer patients were more frequently male and white (74.2% vs. 58.0%, p = 0.114 and 45.2% vs. 25.9%, p = 0.031). Diabetes mellitus was more common in non-cancer patients, but it was associated with increased mortality risk in the cancer group (OR = 2.39, 95% CI: 1.125–5.074). Enterobacteriaceae species were the most frequently isolated organisms (83.0%), with no significant difference between groups. The most common source of infection was genitourinary (49.1%). ICU admission was more frequent in non-cancer patients (49.4% vs. 25.8%, p = 0.024). However, cancer patients had a higher ICU admission mortality risk (OR 2.156, 95% CI: 1.058–4.395) and recent hospitalization rates (67.7% vs. 40.7%, p = 0.011), both associated with increased mortality risk. Cancer patients had a significantly higher 30-day mortality rate (39.0% vs. 16.4%, p = 0.017; OR = 3.012, 95% CI: 1.190–7.622) and hospice admissions (22.6% vs. 3.7%, p = 0.002; OR = 7.583, 95% CI: 1.819–31.618). These findings emphasize the urgent need for early microbiological identification, targeted antimicrobial therapy, and improved infection control strategies. Given the rising prevalence of MDR-GNB pathogens, future research is needed for prompt appropriate antibacterial therapy based on risk stratification and enhanced antimicrobial stewardship programs as these are critical for high-risk cancer patients.


  • Open Access

    Unlocking the Role of Treg Cells Immune Response and Infectious Risk Following CAR T-Cell Therapy in Patients with Cancer

    by Destyn Dicharry, Alexandre E. Malek

    Chimeric antigen receptor (CAR) T-cell therapy has brought hope for patients with cancer and showed promising results and a high cure rate in various types of hematological malignancies. However, cellular therapy can lead to profound immunodeficiency of the innate and adaptive immune systems, whether at the systemic or at the local cellular immune response, which is a major predisposing risk factor for invasive opportunistic infection, including fungal, viral, and bacterial pathogens. The role of regulatory T-cells (Tregs) and their antigen specificity in humans remains largely unknown, but Tregs have been implicated in a wide range of modulating viral and fungal infections. Though there have been many advancements regarding the use of CAR T-cells in treating hematological malignancies, the intricate and homeostatic role of Tregs in influencing therapeutic outcomes and infection risk remains underexplored. Most published literature on this topic focuses on the role of Treg in the immunosuppression necessary for successful CAR T-cell therapy rather than the dual function of Treg in immunosuppression and immune recovery. We intend to bridge this gap with a specific focus on the contribution of Tregs in the modulation of CAR T-cell efficacy and their role in opportunistic infections after therapy. In this review, we described the potential role and dynamics of Tregs following CAR T-cell therapy, offering an expanded understanding of their impact on patient outcomes and highlighting areas for future research.